Replies to post #101507 on Biotech Values

[DewDiligence]

I believe [Rick Shea] said something along the lines that it's harder to partner [M118] because the number of potential partners is more limited now.

That’s old hat (Shea and Wheeler have said it many times) and it’s simply common sense.

Look at the compilation in #msg-53212303 and you’ll see how many Big Pharma are already committed to large and expensive development programs for anticoagulants:

• PFE/BMY: Apixaban
• JNJ/Bayer: Xarelto
• MRK: Betrixaban
• Daiichi Sankyo: Edoxaban
• Boehringer Ingelheim: Pradaxa
• SNY: Otamixaban, AVE5026

These potentially competing programs make the above companies less likely to be avid suitors for M118.